No Data
No Data
Positive Growth Outlook for Medexus Pharmaceuticals Inc. Amid Strategic Expansion and Stable Performance
Medexus Pharmaceuticals Inc. Cut to Hold From Buy by Stifel Nicolaus
Medexus Pharmaceuticals Inc.: Balancing Growth Potential and Risks With a Hold Rating
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (Treosulfan) for Injection in the United States
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (Treosulfan for Injection) in Ontario, Canada
Medexus Schedules Third Fiscal Quarter 2025 Conference Call